While the Italian clinical research community works to an excellent standard of quality, and is relatively competitive in terms of costs, regulatory differences with the rest of Europe pose significant challenges. Mariapia Cirenei and Stefano Marini, president of AICRO and EUCROF respectively, discuss these current challenges, and how the new European clinical trial database and regulation will positively impact the CRO industry in Italy.
How would you assess the competitiveness of Italian CROs overall?
Mariapia Cirenei (MC) - Our researchers, scientists, and clinical research associates are extremely well trained, talented, have significant experience, and overall conduct research of the very highest quality both in the European and global landscape. However, in terms of lead-times there is room for improvement, primarily due to certain regulatory aspects. The homogenization of the Italian regulatory environment with European norms represents a significant opportunity for CROs in Italy, and thus supporting these efforts is the highest priority on our association’s agenda.
Our researchers, scientists, and clinical research associates are extremely well trained, talented, have significant experience, and overall conduct research of the very highest quality both in the European and global landscape
